TrialBritish journal of clinical pharmacology2018

A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.

Valerie Cuvier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.